Focusing on Memogain, Neurodyn Raises $1M
Hoping its leading Alzheimer’s drug candidate will soon be fast-tracked in Europe, Charlottetown drug discovery company Neurodyn Life Sciences Inc. has completed a $1 million funding round.
The company said in a statement Tuesday it will use the funds to support development and commercial initiatives across its product line.
Neurodyn specializes in treating diseases of the brain and has been focusing recently on the commercialization of Memogain, a prescription drug candidate it bought from a German company in 2013. The drug has been shown to increase cognitive processes, both among the